Related Experiment Video
Updated: Aug 9, 2025

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
Published on: October 3, 2019
Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease
Petra Büttner1, Julia Böttner1, Knut Krohn2
1Department of Cardiology, Heart Center Leipzig at University of Leipzig, University of Leipzig, Strümpellstr. 39, 04289 Leipzig, Germany.
Insights
Clonal hematopoiesis (CH) mutations found in blood were also detected in atherosclerotic tissues. This suggests CH mutations may play a role in peripheral vascular disease (PAD) development.
Area of Science:
- Cardiovascular Science
- Hematology
- Genetics
Background:
- Clonal hematopoiesis (CH) mutations are linked to increased atherosclerotic cardiovascular disease risk.
- The presence and local impact of CH mutations in atherosclerosis-associated tissues remain largely unknown.
Purpose of the Study:
- To investigate the presence of CH mutations in peripheral blood and atherosclerotic tissues from patients with peripheral vascular disease (PAD).
Main Methods:
- Pilot study of 31 PAD patients undergoing surgery.
- Next-generation sequencing of common CH-associated genes (DNMT3A, TET2, ASXL1, JAK2) in blood, atherosclerotic lesions, and adjacent tissues.
Main Results:
- CH mutations were detected in 45% of patients' peripheral blood.
- TET2 and DNMT3A were the most frequently mutated genes.
- 88% of blood-detectable CH mutations were also found in atherosclerotic lesions; mutations were also present in perivascular and subcutaneous fat in 12 patients.
Conclusions:
- CH mutations are present in both circulating blood and atherosclerotic tissues in PAD patients.
- These findings suggest a potential novel contribution of CH mutations to PAD pathogenesis.
Abstract:
Clonal hematopoiesis (CH)-associated mutations increase the risk of atherosclerotic cardiovascular diseases. However, it is unclear whether the mutations detected in circulating blood cells can also be detected in tissues associated with atherosclerosis, where they could affect physiology locally. To address this, the presence of CH mutations in peripheral blood, atherosclerotic lesions and associated tissues was assessed in a pilot study of 31 consecutive patients with peripheral vascular disease (PAD) who underwent open surgical procedures. Next-generation sequencing was used to screen the most commonly mutated loci (DNMT3A, TET2, ASXL1 and JAK2). Twenty CH mutations were detected in peripheral blood of 14 (45%) patients, 5 of whom had more than one mutation. TET2 (11 mutations, 55%) and DNMT3A (8 mutations, 40%) were the most frequently affected genes. Altogether, 88% of the mutations detectable in peripheral blood were also present in the atherosclerotic lesions. Twelve patients also had mutations in perivascular fat or subcutaneous tissue. The presence of CH mutations in PAD-associated tissues as well as in blood suggests that CH mutations may make a previously unknown contribution to PAD disease biology.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Atherosclerosis I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction

